FBR Capital Downgrades MetLife (MET) to Market Perform
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
FBR Capital downgraded MetLife (NYSE: MET) from Outperform to Market Perform while maintaining a price target of $54.00.
Analyst Randy Binner commented, "Our analysis shows MET shares efficiently discounting spread, tax, and deregulation factors post election, which we model as benefiting the stock price by $7/share. Thus, the risk/reward has become much less attractive. At the same time, the upcoming spin catalyst and associated buyback are now better priced into shares. MET is trading at 100% of its five-year min/max P/E valuation."
Shares of MetLife closed at $55.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Cuts Teva Pharma (TEVA) to Neutral Amid Challenging Generic Environment
- Zayo Group Holdings (ZAYO) PT Raised to $41 at BTIG; Reiterates Buy
- UPDATE: SunTrust Robinson Humphrey Downgrades Simon Property Group (SPG) to Hold
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!